Definium Therapeutics Sees Unusually High Options Volume (NASDAQ:DFTX)

Definium Therapeutics, Inc. (NASDAQ:DFTX) was the target of unusually large options trading activity on Friday. Traders purchased 9,041 call options on the company. This is an increase of approximately 292% compared to the typical volume of 2,306 call options.

Definium Therapeutics Price Performance

Shares of Definium Therapeutics stock traded down $1.38 during trading hours on Friday, reaching $47.07. The stock had a trading volume of 2,555,622 shares, compared to its average volume of 4,602,458. The stock’s 50 day moving average is $29.22 and its 200 day moving average is $21.67. The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.15. Definium Therapeutics has a twelve month low of $7.76 and a twelve month high of $49.20. The firm has a market capitalization of $4.69 billion, a PE ratio of -18.90 and a beta of 2.20.

Definium Therapeutics (NASDAQ:DFTX) last posted its earnings results on Friday, May 8th. The company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.23). Equities analysts expect that Definium Therapeutics will post -2.27 earnings per share for the current fiscal year.

Insider Activity at Definium Therapeutics

In related news, CFO Brandi Roberts sold 3,013 shares of the firm’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $135,675.39. Following the completion of the transaction, the chief financial officer owned 209,487 shares in the company, valued at $9,433,199.61. This trade represents a 1.42% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Matthew T. Wiley sold 2,867 shares of the firm’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $129,101.01. Following the completion of the transaction, the insider owned 174,633 shares of the company’s stock, valued at $7,863,723.99. This trade represents a 1.62% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 48,096 shares of company stock valued at $2,165,763. 2.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Definium Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Palumbo Wealth Management LLC lifted its position in shares of Definium Therapeutics by 18.4% during the 4th quarter. Palumbo Wealth Management LLC now owns 39,002 shares of the company’s stock valued at $522,000 after buying an additional 6,073 shares in the last quarter. Flagship Harbor Advisors LLC purchased a new stake in Definium Therapeutics in the 4th quarter worth $117,000. Bay Rivers Group increased its holdings in Definium Therapeutics by 14.3% in the 4th quarter. Bay Rivers Group now owns 16,001 shares of the company’s stock worth $214,000 after acquiring an additional 2,000 shares in the last quarter. FNY Investment Advisers LLC acquired a new position in Definium Therapeutics during the third quarter worth $107,000. Finally, Caxton Associates LLP acquired a new position in Definium Therapeutics during the third quarter worth $126,000. 27.91% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on DFTX shares. Piper Sandler reissued an “overweight” rating and issued a $48.00 price objective (down from $49.00) on shares of Definium Therapeutics in a report on Friday, May 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Definium Therapeutics in a report on Tuesday, April 21st. Leerink Partners set a $52.00 target price on Definium Therapeutics and gave the company an “outperform” rating in a research report on Monday, June 22nd. Robert W. Baird upped their target price on Definium Therapeutics from $37.00 to $57.00 and gave the company an “outperform” rating in a research report on Tuesday, June 23rd. Finally, JonesTrading increased their price target on shares of Definium Therapeutics from $61.00 to $74.00 and gave the stock a “buy” rating in a report on Wednesday, June 24th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Definium Therapeutics presently has a consensus rating of “Buy” and an average target price of $49.23.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.